( July 10, 2025, 12:16 PM EDT) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel affirmed a New Jersey federal judge’s finding that two appellant medicine makers failed to show that claims in a patent related to dosing regimens for an injectable schizophrenia treatment were invalid as obvious, holding that it saw no error in the judge’s analysis of the motivation to combine prior art references....